Fundraising Fox

EurekaBio

Shenzhen, CN · 3 known investors

EurekaBio develops technologies and solutions for the cell and gene therapy (CGT) industry, focused on treatments for diseases such as cancer, rare diseases, genetic disorders, and auto-immune conditions. The company positions itself as a provider of comprehensive, research-driven solutions to CGT challenges.

BiotechDeep TechHardwareHealthtechMedical Devices

Investors · 3

F-Prime CapitalCambridge · $3M – $10M
Ming capitalShenzhen

Also in the syndicate · 1

YUEXIU INDUSTRIAL FUNDlead

Funding

SEC filings, press & company announcements
  • Undisclosed amountSeries B+Mar 2024

    YUEXIU INDUSTRIAL FUND (lead)

    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Competitors · 1

by search overlap
Eureka Therapeutics8 shared keywordsEureka Therapeutics is a clinical-stage biopharmaceutical company developing T-cell-based therapies to treat solid tumors and other cancers. Its pipeline is built on the ARTEMIS and E-ALPHA technology platforms aimed at targeting cancer-specific antigens.

Companies competing with EurekaBio for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

EurekaBio Completes $40 Million Series B+ Financing to Advance EuLV™ Lentiviral Vector Production System - BioSpacebiospace.com · Mar 2024

Frequently asked questions

What does EurekaBio do?
EurekaBio develops technologies and solutions for the cell and gene therapy (CGT) industry, focused on treatments for diseases such as cancer, rare diseases, genetic disorders, and auto-immune conditions. The company positions itself as a provider of comprehensive, research-driven solutions to CGT challenges.
Who are EurekaBio's investors?
EurekaBio's investors include F-Prime Capital, Ming capital.
Where is EurekaBio headquartered?
EurekaBio is headquartered in Shenzhen, CN.